167 related articles for article (PubMed ID: 35795155)
1. Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom.
Owusu-Edusei K; Palmer C; Ovcinnikova O; Favato G; Daniels V
J Health Econ Outcomes Res; 2022; 9(1):140-150. PubMed ID: 35795155
[No Abstract] [Full Text] [Related]
2. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the cost-effectiveness of HPV vaccination for adolescent girls in Japan: A comparison of 2-valent, 4-valent, and 9-valent HPV vaccines with consideration of cross-protection.
Choi W; Shim E
Prev Med; 2024 Jan; 178():107743. PubMed ID: 37866695
[TBL] [Abstract][Full Text] [Related]
4. The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.
Chesson HW; Markowitz LE; Hariri S; Ekwueme DU; Saraiya M
Hum Vaccin Immunother; 2016 Jun; 12(6):1363-72. PubMed ID: 26890978
[TBL] [Abstract][Full Text] [Related]
5. Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.
Simoens S; Bento-Abreu A; Merckx B; Joubert S; Vermeersch S; Pavelyev A; Varga S; Morais E
Front Pharmacol; 2021; 12():628434. PubMed ID: 33912045
[No Abstract] [Full Text] [Related]
6. The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong.
Cheung TH; Cheng SSY; Hsu DC; Wong QW; Pavelyev A; Walia A; Saxena K; Prabhu VS
Cost Eff Resour Alloc; 2021 Nov; 19(1):75. PubMed ID: 34801050
[TBL] [Abstract][Full Text] [Related]
7. Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine.
Chesson HW; Laprise JF; Brisson M; Markowitz LE
J Infect Dis; 2016 Jun; 213(11):1694-700. PubMed ID: 26908738
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia.
Mahumud RA; Alam K; Dunn J; Gow J
PLoS One; 2019; 14(10):e0223658. PubMed ID: 31596899
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country setting.
Termrungruanglert W; Khemapech N; Vasuratna A; Havanond P; Tantitamit T
J Gynecol Oncol; 2024 Apr; ():. PubMed ID: 38670561
[TBL] [Abstract][Full Text] [Related]
10. Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France.
Majed L; Bresse X; El Mouaddin N; Schmidt A; Daniels VJ; Pavelyev A; Levy-Bachelot L; Elbasha E
Vaccine; 2021 Jan; 39(2):438-446. PubMed ID: 33261895
[TBL] [Abstract][Full Text] [Related]
11. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain.
De La Fuente J; Hernandez Aguado JJ; San Martín M; Ramirez Boix P; Cedillo Gómez S; López N
Hum Vaccin Immunother; 2019; 15(7-8):1949-1961. PubMed ID: 30698488
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia.
Wondimu A; Postma MJ; van Hulst M
Vaccine; 2022 Mar; 40(14):2161-2167. PubMed ID: 35248423
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
14. Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong.
Cheung TH; Cheng SSY; Hsu D; Wing-Lei Wong Q; Pavelyev A; Sukarom I; Saxena K
Hum Vaccin Immunother; 2023 Aug; 19(2):2184605. PubMed ID: 37183965
[TBL] [Abstract][Full Text] [Related]
15. Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom.
Daniels V; Saxena K; Patterson-Lomba O; Gomez-Lievano A; Saah A; Luxembourg A; Velicer C; Chen YT; Elbasha E
Vaccine; 2022 Mar; 40(14):2173-2183. PubMed ID: 35232593
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain.
Linertová R; Guirado-Fuentes C; Mar-Medina J; Teljeur C
Hum Vaccin Immunother; 2022 Nov; 18(6):2127983. PubMed ID: 36347243
[TBL] [Abstract][Full Text] [Related]
17. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries.
Kiatpongsan S; Kim JJ
PLoS One; 2014; 9(9):e106836. PubMed ID: 25198104
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model.
Chesson HW; Meites E; Ekwueme DU; Saraiya M; Markowitz LE
Vaccine; 2020 Nov; 38(50):8032-8039. PubMed ID: 33121846
[TBL] [Abstract][Full Text] [Related]
19. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.
Brisson M; Laprise JF; Chesson HW; Drolet M; Malagón T; Boily MC; Markowitz LE
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26438574
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy.
Mennini FS; Bonanni P; Bianic F; de Waure C; Baio G; Plazzotta G; Uhart M; Rinaldi A; Largeron N
Cost Eff Resour Alloc; 2017; 15():11. PubMed ID: 28701899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
